TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02122770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous solution.
Study: NCT02685501

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention
Study: NCT02396017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy
Description: Endoscopic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: Endoscopic device

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol
Description: Bowel purgative

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol
Description: Bowel purgative
Study: NCT01325116

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Reminder
Description: Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Reminder
Description: Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
Study: NCT00732979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infrahepatic inferior vena cava clamping
Description: The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No infrahepatic inferior vena cava clamping
Description: Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below \< 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
Study: NCT01044511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visits
Description: home visits by specialist nurse 2 times and 1 phonecall

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: hotline
Study: NCT00867828

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Neptune Krill Oil
Description: Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (soy oil)
Description: Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
Study: NCT02632240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery:The tunnel technique for covering gingival recession
Description: The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgery:The tunnel technique for covering gingival recession
Description: The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
Study: NCT02916394

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-ZIGF-1R:4：40
Description: No Intervention

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-ZIGF-1R:4：40
Description: No Intervention

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-ZIGF-1R:4：40
Description: No Intervention

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-NODAGA-ZIGF-1R:4：40
Description: No Intervention
Study: NCT02066818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine/tetracaine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% lidocaine
Study: NCT02706886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).
Study: NCT04420585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Two desmopressin 0.2 mg tablets at bedtime for 14 days and monitoring if \<50 % improvement
Study: NCT01529541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anagliptin
Description: Anagliptin 100mg, tablet, twice a day (BID)
Study: NCT01655849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: z160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02491372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
Study: NCT03871738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: The intervention to the experimental group will consist of the application of the protocol of proprioception exercises. Before the exercises of the protocol, a warm-up will be carried out that will last 3 minutes and consists of exercises of joint mobility and jumping rope.~The protocol consists in carrying out two exercises per session, of 10 minutes each. A minute of rest will be implemented between the warm-up and the completion of the protocol, in addition to one minute between the two proprioception exercises in each session. The exercises will vary from week to week, and all the protocol exercises should be done barefoot. The exercise protocol proposed in this study consists of a total of 7 exercises: of unipodal and bipodal support, with unstable surfaces and postural changes.
Study: NCT02673801

Intervention type: OTHER
Intervention: Orthopedic assessment in the outpatient clinic
Description: Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
Study: NCT03673345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N3) and 2 influenza B subtypes (B Yamata lineage B Victoria lineage).
Study: NCT03846115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Led Seeking Safety app
Description: This app offers participants sessions of Seeking Safety plus enhanced app features designed to engage and sustain participants in their recovery work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control app
Description: This app offers the Seeking Safety content but without the enhanced features
Study: NCT02631460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 80-120 mg/d
Description: d1, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed 500 mg/m2
Description: d1, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin AUC=5
Description: d1, every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin AUC=5
Description: d1, every 3 weeks
Study: NCT02998385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intravenous, concomitant to irradiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week
Study: NCT01746498

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct current stimulation using Anodal electrode
Description: 11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: direct current stimulation using cathodal electrode
Description: 11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham direct current stimulation
Description: 11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
Study: NCT01665846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
Study: NCT04128722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus Oral Liquid Product 1mg/mL
Description: 0.5 mL to 1 mL according to the size of the lesion, once daily, on lingual microcystic lymphatic malformation
Study: NCT03051698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1-inhibitor
Description: 100 Unit/kg IV, one gift prior to broncho provocation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: vancomycin, ciprofloxacin, metronidazole
Study: NCT02317835

Intervention type: DEVICE
Group type: OTHER
Intervention: DFUPS
Description: The DFUPS device is a two-camera instrument for capturing images of feet
Study: NCT04145375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694
Description: Up to 120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160mg
Study: NCT03542331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipiodol
Description: Endometrial flushing with Lipiodol between day 6 and 8 of the cycle

Intervention type: DEVICE
Group type: OTHER
Intervention: Mock catheter
Description: Introduction of a mock catheter in the uterus between day 6 and 8 of the cycle
Study: NCT04058106

Intervention type: PROCEDURE
Intervention: A patient who need the cerebral artery aneurysm clipping surgery
Description: A patient who go the propofol based total intravenous anesthesia due to intraoperative neuromonitorung for unruptured cerebral artery aneurysm clipping surgery
Study: NCT03270475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: subjects complete 4-5 weeks of training
Study: NCT02035748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocriplasmin
Description: 0.5 mg/0.2 mL solution for injection
Study: NCT01115556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 2.0 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg
Study: NCT01944618

Intervention type: DRUG
Intervention: Forxiga
Description: FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor \[DPP 4 inhibitor\] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
Study: NCT03794102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: Sterile water irrigation from standard sterile water bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: 0.9% saline irrigation from standard saline bags will be used during ureteroscopy. Pulsed irrigation of the irrigant fluid with hand-held syringes will be used in all cases according to standard practice in order to visualize the upper urinary tract during the ureteroscopy procedure.
Study: NCT02319967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPE
Description: Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAPE
Description: Decision support and communication tool to promote guideline-recommended care by providers and use of such care by children/caregivers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW home visits
Description: Home visits by community health workers (CHW) to assist children and their caregivers to implement the CAPE and other guideline-recommended competencies.
Study: NCT02824016

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biological sample
Description: T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: biological sample
Description: T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: supraclavicular irradiation
Description: Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
Study: NCT00655473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (RO4607381)
Description: 600mg po daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po daily for 24 months
Study: NCT03958214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recipe 4 Success
Description: Home visitors teach parents about children's self-regulation skills and healthy eating habits. The home visitors then teach parents how to sensitively scaffold the development of their toddlers' self-regulation skills in the context of cooking and snack preparation lessons. Prior research shows that self-regulation skills in early childhood predict long-term health indicators, such as BMI. Prior research also shows that children who are involved in the preparation of healthier foods are more likely to eat them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual practice Early Head Start
Description: Home visitors will continue to deliver usual practice Early Head Start home visits that follow a standard curriculum and are tailored on an ongoing basis to meet individual family needs.
Study: NCT04144036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 3 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 6 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab, 9 mg/kg
Description: The doses for the 3 + 3 design (dose escalation phase) are listed in the arm description. The dose-expansion phase will use the maximum-tolerated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neihulizumab
Description: This arm will receive the Maximum Tolerated Dose determined in the Drug Escalation phase.